Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @galderma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @galderma
-
Galderma is Empowering Individuality in the new global campaign launched at IMCAS congress in Paris this week. Meet the different faces for our entire product portfolio. To learn more about the campaign and Galderma´s aesthetic products visit http://www.GaldermaAesthetics.com
#Aestheticspic.twitter.com/BkLCcsdJCW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Where is the Aesthetic industry going? Galderma VP Alexandre Brennan at IMCAS' World Economic Tribune panel discussion today, January 31, 15:30-18:30
#Aestheticspic.twitter.com/UL9mEQZ4t6
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Join GALDERMA and our GAIN Faculty for an afternoon symposium “Empowering Personalization through the Decades”, Jan 30, at 14:00, Amphi Bleu, Level 2
#Aestheticspic.twitter.com/H8qqqbHURs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Three days in beautiful Paris! Galderma is Empowering Individuality at IMCAS congress in Paris this week.
#Aestheticspic.twitter.com/svxau08NcM
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Galderma is Empowering Individuality at IMCAS congress in Paris this week starting tomorrow. Visit us at booth n°P254 on level 2
#Aestheticspic.twitter.com/R9v50Vym3W
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Wishing you and yours all the very best for 2020 as we commence this new decade as the world’s largest independent dermatology company. Follow us to keep up to date with our Galderma journey.
#dermatology#healthpic.twitter.com/MNC9m8GTJF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We received a positive outcome through the European Decentralised Procedure for AKLIEF® (trifarotene 50 mcg/g cream), the first new retinoid molecule for acne in the European Union in 25 years https://www.galderma.com/news/galderma-receives-positive-outcome-through-european-decentralised-procedure-akliefr …
#dermatologypic.twitter.com/KHHo6SlA5g
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Investigational therapy Nemolizumab granted FDA Breakthrough Therapy Designation for the treatment of patients suffering from prurigo nodularis https://www.galderma.com/news/galderma-investigational-therapy-nemolizumab-granted-fda-breakthrough-therapy-designation …
#dermatologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Good nutrition is essential for healthy skin.
#health#dermatologypic.twitter.com/Fx2qVL7oq9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$180,000 was raised by Galderma’s 5th Annual Wonder Run, benefiting Children’s Skin Disease Foundation and Camp Wonder, now entering its 20th year! Check out a video from the event held in Fort Worth, TX.
#wearegalderma#campwonder#childhoodwithoutlimitspic.twitter.com/KJJ6OgQiU2Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Good nutrition is essential for healthy skin.
#health#dermatologypic.twitter.com/F1U4se6lwJ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Psoriasis is a chronic inflammatory skin disease, usually genetically predisposed.
#health#dermatologypic.twitter.com/UPVFiFfsLf
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Over the past years, the incidence of non-melanoma and melanoma skin cancers has continued to increase across the globe. The prevention and treatment of skin cancer is one of our key focus areas.
#Health#dermatologypic.twitter.com/pSnArBfm95
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Face Up To Rosacea: Galderma launches new campaign to empower and equip rosacea patients to discuss the true burden of their disease with a dermatologist https://www.galderma.com/news/face-rosacea-galderma-launches-new-campaign-empower-and-equip-rosacea-patients-discuss-true …
#dermatologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you for visiting our booth and for attending our symposium dedicated to a devastating disease, prurigo nodularis during the
#EADV2019#eadv#dermatologypic.twitter.com/cqWqUeOw9k
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you to everyone who attended our
#EADV2019#rosacea Meet The Expert session. Visit us in Hall 8 if you would like to find out more about Galderma’s commitment to skin health#DermatologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Prof. Dr. Martin Schaller highlights how the latest ROSacea Consensus (ROSCO) expert recommend treatment algorithm has simplified the task of effective
#rosacea#diagnosis & treatment by addressing the multiple features of rosacea and aiming for ‘clear’ (IGA 0) skin#EADV2019Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Prof. Dr. Martin Schaller highlights how the phenotype approach can help reach the correct diagnosis for
#rosacea patients & make aiming for ‘clear’ (IGA 0) skin a possibility, reducing disease burden and improving quality of life#EADV2019#dermatologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are excited to host a 2nd Meet The Expert session at
#EADV2019 today. Prof. Dr. Martin Schaller will discuss optimizing treatment outcomes for#rosacea patients & aiming for ‘clear’ (IGA 0) skin, building on latest ROSacea Consensus (ROSCO) panel recommendations#dermatologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.